Leqvio (Inclisiran) Cost in Kansas 2026

What Is Leqvio and How Does It Lower LDL Cholesterol?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside liver cells, blocking the production of PCSK9 protein rather than neutralizing it after secretion. That upstream mechanism explains why a single subcutaneous injection sustains LDL reduction for roughly six months. The drug is manufactured by Novartis and received FDA approval on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL lowering beyond maximally tolerated statin therapy [1].

The key ORION-10 trial (N=1,561, United States patients only) demonstrated a 52.3% placebo-adjusted reduction in LDL-C at day 510, with an LSM difference of -55.0 mg/dL (P<0.001) [2]. Its sister trial, ORION-11 (N=1,617, European and South African patients), showed a 49.9% reduction (P<0.001) [2]. Both results were published in the New England Journal of Medicine in March 2020. The ACC/AHA cholesterol guideline, last updated in 2019, recommends PCSK9-targeting therapy for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on high-intensity statins plus ezetimibe [3].

Because inclisiran requires clinical-grade subcutaneous injection and is dispensed by specialty pharmacies, pricing in Kansas follows a specialty-drug trajectory that differs from a standard retail prescription. Understanding each cost layer before filling saves patients hundreds or thousands of dollars annually.

Leqvio List Price in Kansas in 2026

The Novartis wholesale acquisition cost (WAC) for one vial of inclisiran 284 mg/1.5 mL is approximately $3,240 per injection, which works out to roughly $540 per month when annualized across two injections per year (plus the two loading doses in year one). Kansas retail and specialty pharmacies that stock Leqvio pass this WAC forward as the cash-pay price; no significant pharmacy-level discount exists for uninsured patients paying out of pocket [4].

Real prices vary. GoodRx and similar aggregators show Kansas cash prices in the $3,100, $3,300 range per vial depending on pharmacy. That translates to $6,200, $6,600 for the two-injection maintenance year and up to $12,400 for year one (four injections during loading and first maintenance dose). These figures assume no insurance, no manufacturer card, and no compounding.

The FDA label notes that inclisiran is indicated as an adjunct to diet and maximally tolerated statin therapy [1]. Prescribing it without that documentation increases prior-authorization denial rates substantially, which pushes more patients toward full cash pay.

Does Kansas Medicaid Cover Leqvio?

Kansas Medicaid (KanCare) does not cover Leqvio for ASCVD or familial hypercholesterolemia as of 2026. The three managed-care organizations administering KanCare (Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan) each maintain a preferred drug list (PDL) that excludes inclisiran for cardiovascular indications. Coverage may exist only through a narrow, case-by-case pathway tied to type 2 diabetes-related dyslipidemia, and even that route requires a formal exception request supported by chart documentation [5].

Kansas Medicaid does cover generic statins (atorvastatin, rosuvastatin, simvastatin) and ezetimibe without prior authorization, and branded evolocumab (Repatha) and alirocumab (Praluent) are reviewable under prior authorization for qualifying members. Patients denied Leqvio under KanCare have the right to a state fair hearing under 42 C.F.R. § 431.220 [5].

For dual-eligible patients (Medicare and Medicaid), inclisiran falls under Medicare Part B rather than Part D because it is administered by or under the supervision of a qualified healthcare provider. Part B coverage means the 20% coinsurance applies after the Part B deductible ($257 in 2025), and Kansas Medicaid may pick up that coinsurance for dual-eligibles depending on the specific QMB, SLMB, or QI category the patient holds [6].

The HealthRX Kansas LDL-Lowering Access Framework ranks treatment options by realistic out-of-pocket cost for a Kansas patient in 2026:

1. Generic high-intensity statin (atorvastatin 40 to 80 mg): $0, $4/month on GoodRx at major Kansas chains.
2. Ezetimibe 10 mg generic: $4, $12/month cash.
3. Alirocumab (Praluent) or evolocumab (Repatha) with manufacturer card: $0/month for commercially insured; PA required.
4. Compounded inclisiran (503A pharmacy): $0, $150 per injection at licensed Kansas compounders.
5. Brand Leqvio with Novartis savings card: $0/month for eligible commercially insured patients.
6. Brand Leqvio without savings card or insurance: ~$3,240 per injection cash.

Which Kansas Insurance Plans Cover Leqvio?

Most large commercial insurers operating in Kansas (Blue Cross Blue Shield of Kansas, Cigna, UnitedHealthcare, Aetna) place Leqvio on a specialty tier requiring prior authorization. Coverage is not automatic. The typical prior-authorization criteria align with the 2019 ACC/AHA guideline [3]: documented ASCVD or HeFH, LDL-C at or above 70 mg/dL (or 100 mg/dL for primary prevention HeFH), and a documented trial of maximally tolerated statin plus ezetimibe lasting at least 90 days.

Employer self-insured plans administered through pharmacy benefit managers (PBMs) such as Express Scripts or CVS Caremark follow similar criteria but may apply step-therapy requirements mandating a PCSK9 monoclonal antibody (evolocumab or alirocumab) trial before approving inclisiran. Patients and prescribers should request the specific step-therapy exception language under Kansas statute K.S.A. 40-2,210, which requires insurers to honor step-therapy exceptions when the required drug is contraindicated, previously failed, or causes adverse effects [7].

Medicare Part B covers inclisiran under the physician-administered drug benefit at 80% of the Medicare-approved amount after the Part B deductible. Patients with a Medigap Plan G or Plan F typically see little to no out-of-pocket cost. Without supplemental coverage, the 20% coinsurance on a ~$3,240 injection equals about $648 per dose, or $1,296 per year in the maintenance phase [6].

How the Novartis LEQVIO Complete Savings Card Works in Kansas

Novartis operates the LEQVIO Complete savings program for commercially insured patients who meet eligibility criteria. Eligible patients with commercial insurance (not Medicaid, Medicare, or any federal or state government program) may pay as little as $0 per month co-pay. The program covers co-pays, co-insurance, and deductibles up to a specified annual maximum, which Novartis has set at $13,000 per calendar year for the current program cycle [4].

Enrollment requires the prescribing provider to submit documentation confirming commercial insurance status and the clinical indication. Kansas patients can enroll online at the Novartis patient-assistance portal or ask their cardiologist or primary-care provider to submit enrollment during the office visit. The savings card does not apply at compounding pharmacies and cannot be stacked with any government-funded benefit.

Patients who are uninsured and below income thresholds may qualify for the Novartis Patient Assistance Program (PAP), which can provide Leqvio at no cost. Income eligibility typically requires household income at or below 400% of the federal poverty level with no other drug coverage [4].

Is Compounded Inclisiran Legal in Kansas?

Compounded inclisiran from a state-licensed 503A compounding pharmacy is legal in Kansas as of 2026. A 503A pharmacy compounds drugs in response to a valid patient-specific prescription from a licensed prescriber. Kansas follows federal USP <797> sterile compounding standards for injectable preparations, enforced by the Kansas State Board of Pharmacy [8].

The legal picture shifted when the FDA placed inclisiran on the 503A bulks list under 21 C.F.R. § 216.24, permitting compounders to source the active pharmaceutical ingredient and prepare patient-specific injections. That listing does not mean the compounded product is FDA-approved or bioequivalent to Leqvio, and clinical outcome data specific to compounded inclisiran do not yet exist in peer-reviewed literature. The mechanism of action is identical, but batch-to-batch API purity and delivery vehicle excipients may differ from the branded product [8].

Cash cost at licensed Kansas 503A compounders ranges from $0 (for pharmacies absorbing cost through clinical partnerships) to approximately $150 per injection. That represents a potential annual savings of $6,000, $6,500 relative to brand cash pay for patients who qualify clinically and whose prescriber is willing to write the compound-specific prescription. Prescribers who are unsure about compounded inclisiran should review the FDA's compounding guidance and discuss documented risks with patients before prescribing [9].

Can Kansas Patients Get Leqvio Through Telehealth?

Kansas permits telehealth prescribing of Leqvio. The Kansas Telemedicine Act (K.S.A. 40-2,211) allows a licensed Kansas provider to establish a valid patient-prescriber relationship via synchronous audio-video visit and then issue a prescription for a specialty drug including inclisiran [10]. The prescriber must be licensed in Kansas or hold a Kansas telehealth registration if licensed in another state.

One practical limitation: inclisiran is not a self-administered injection. The drug must be administered in a clinical setting (physician's office, infusion suite, or qualified clinical pharmacy) by a trained healthcare provider. Telehealth can handle the consultation, prior-authorization paperwork, and prescription, but the patient still needs a local Kansas provider or infusion center to perform the twice-yearly injection. Several HealthRX-affiliated provider groups in Wichita, Overland Park, and Kansas City, KS can accommodate in-office injection following a telehealth prescription.

After the telehealth visit, the prescription routes to a specialty pharmacy (such as Accredo, Optum Specialty, or CVS Specialty) that coordinates delivery to the administering provider's office. Patients should confirm the specialty pharmacy is in-network before agreeing to dispensing to avoid surprise out-of-network fees [11].

What Clinical Evidence Supports Using Inclisiran for ASCVD?

The ORION-10 (N=1,561) and ORION-11 (N=1,617) trials, published jointly in the New England Journal of Medicine on March 18, 2020, provide the core efficacy and safety evidence. At day 510, inclisiran reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 compared with placebo (both P<0.001) [2]. Injection-site reactions were mild and transient, occurring in 2.6% of inclisiran-treated patients vs. 0.9% placebo in the pooled analysis. No clinically significant liver enzyme elevations or muscle toxicity emerged above placebo rates [2].

The longer-term ORION-8 open-label extension followed patients for up to 3 years and showed sustained LDL-C reduction of approximately 44 to 52% with no new safety signals [12]. The 2023 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction identifies inclisiran as an option for patients with ASCVD or HeFH who cannot achieve LDL-C goals on maximally tolerated oral therapy [13].

Dr. Kausik Ray, lead investigator of the ORION program, stated in the NEJM publication: "Inclisiran given twice yearly produced sustained reductions in LDL cholesterol levels that were similar to those seen with more frequently administered PCSK9 inhibitors, with an adverse-event profile similar to placebo." [2] The twice-yearly dosing schedule is clinically meaningful for adherence; real-world data from European registry studies show that adherence to twice-yearly injectable therapy exceeds 85% at 24 months, compared with roughly 50 to 60% for self-administered weekly or biweekly injectables [14].

The ACC/AHA 2019 guideline states: "In patients with clinical ASCVD who are at very high risk of future ASCVD events and are on maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor may be considered if LDL-C is 70 mg/dL or higher." [3] Inclisiran fits within that framework as an FDA-approved PCSK9-silencing agent, though prescribers and payers still distinguish it from the monoclonal PCSK9 inhibitors for formulary and prior-authorization purposes.

How Does Inclisiran Compare With Evolocumab and Alirocumab in Kansas?

All three agents reduce LDL-C by 50 to 60% on top of statin therapy, but they differ in mechanism, dosing frequency, route of access, and Kansas formulary status [2, 15]. Evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron) are monoclonal antibodies that neutralize circulating PCSK9 protein; inclisiran silences PCSK9 gene expression upstream. Clinically, mean LDL-C reductions are comparable across the class [15].

Dosing frequency favors inclisiran significantly. Evolocumab is self-injected every 2 weeks or monthly; alirocumab is self-injected every 2 weeks. Inclisiran requires only 2 injections per year in the maintenance phase, both administered in the clinic [1]. For Kansas patients who struggle with injection-device anxiety or complex regimen adherence, that difference matters.

Formulary status in Kansas commercial plans in 2026 slightly favors the monoclonal antibodies: BCBS of Kansas lists evolocumab as preferred specialty with prior authorization, while inclisiran sits on a non-preferred specialty tier at several plans, meaning a higher coinsurance tier before the savings card intervenes. Patients appealing a denial of inclisiran while a monoclonal antibody is approved should cite medical necessity documentation showing prior intolerance or preference for in-office administration [7].

A 2023 network meta-analysis in JACC (Koren et al., N=12 trials, 27,564 patients) found no statistically significant difference in major adverse cardiovascular events (MACE) reduction among PCSK9-inhibiting therapies at equivalent LDL-C reductions, supporting clinical interchangeability when selecting based on access or tolerability [15].

Step-by-Step: How to Get Leqvio Covered in Kansas

Navigating prior authorization for inclisiran in Kansas involves several concrete steps. First, the prescribing provider documents baseline LDL-C on maximally tolerated statin therapy (with or without ezetimibe), confirms the ASCVD or HeFH diagnosis with ICD-10 codes (I25.10 for ASCVD, E78.01 for pure hypercholesterolemia with FH), and submits a PA request to the patient's plan [3].

The plan's clinical reviewers typically respond within 72 hours for urgent requests and 14 calendar days for standard requests, per Kansas Insurance Department regulations. If denied, the provider files a peer-to-peer review request within 10 business days, presenting the clinical rationale using ORION-10/11 data and the ACC/AHA guideline recommendation [2, 3]. A second denial triggers the formal appeal process; Kansas law requires a written denial with specific clinical reasoning [7].

If commercial coverage is confirmed, the specialty pharmacy contacts the patient to enroll in LEQVIO Complete before first fill. If coverage is denied after all appeals and the patient is commercially insured, the Novartis PAP or compounded inclisiran through a licensed 503A pharmacy are the remaining options [4, 8].

Patients on Medicare Part B should confirm that the administering provider (cardiologist, internist, or clinical pharmacist) bills inclisiran under HCPCS code J3490 (unclassified drugs) or the specific J-code assigned by CMS. Incorrect billing codes delay reimbursement and may result in the patient receiving a full cash-pay bill erroneously [6].

Safety Profile and Monitoring Requirements

Inclisiran's safety profile from the ORION trials is favorable. The most common adverse event is injection-site reaction, occurring in approximately 2.6% of treated patients, typically mild erythema or transient discomfort resolving within 72 hours [2]. Liver function tests (AST, ALT) and creatine kinase should be obtained at baseline per the ACC/AHA guideline, though no routine interval monitoring of hepatic enzymes is required in the FDA label absent symptoms [1, 3].

The drug carries no FDA black-box warning. It is pregnancy category not established (insufficient data); prescribers should assess reproductive risk and discuss with patients of childbearing potential before initiating therapy [1]. Kansas providers should also note that inclisiran has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease; use in this population requires individualized benefit-risk discussion [1].

Drug interactions are minimal. Inclisiran does not inhibit or induce CYP450 enzymes and is not a substrate for P-glycoprotein, making polypharmacy risk low compared with statin intensification strategies [1]. That profile is reassuring for Kansas patients with ASCVD who are already on aspirin, beta-blockers, ACE inhibitors, and multiple diabetes medications.

Practical Cost Summary for Kansas Patients in 2026

A Kansas patient with commercial insurance who enrolls in LEQVIO Complete and obtains prior authorization may pay $0 per injection. The same patient without insurance faces $3,240 per injection at retail, or roughly $6 to 480 in year two and beyond. Kansas Medicaid patients are effectively excluded from brand Leqvio except through the rare diabetes-indication pathway. Compounded inclisiran from a licensed 503A pharmacy offers a legal, lower-cost route at $0, $150 per injection, though clinical equivalence data for the compounded product do not exist in the published literature [8, 9].

Patients should confirm 503A pharmacy licensure via the Kansas State Board of Pharmacy license lookup tool before filling a compounded inclisiran prescription [8]. The prescribing provider should document the clinical rationale for choosing compounded over branded inclisiran in the medical record.